OSRH · OSR Health, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-09-17 | Fierz Reto Kaspar |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-14 | Cho Joong Myung |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-14 | Kim Sang Harry |
See Remarks |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents 430,000 private placement rights which were converted into 43,000 shares of common stock at the closing of the business combination between Bellevue Life Science Acquisition Corp. and OSR Holdings Co., Ltd. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
43,000 |
| 2025-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents shares of OSR Holdings, Inc. common stock acquired by BCM Europe AG in exchange for its shares of OSR Holdings Co., Ltd. common stock at the closing of the business combination between Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd. Represents shares of common stock held by BCM Europe AG. BCM Europe AG is a wholly-owned subsidiary of Bellevue Capital Management LLC. Kuk Hyoun Hwang is the managing partner of Bellevue Capital Management LLC and has voting and dispositive power over the shares held by BCM Europe AG. |
Common Stock
(I)
|
7,531,634 |
| 2025-02-14 | Barberis Alcide |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-14 | Jee Hyuk Joo |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Direct)
Represents 430,000 private placement rights which were converted into 43,000 shares of common stock at the closing of a business combination between Bellevue Life Science Acquisition Corp. and OSR Holdings Co., Ltd. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
43,000 |
| 2025-02-14 | Bang Gihyoun |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents shares of OSR Holdings, Inc. common stock acquired by Bellevue Capital Management LLC in exchange for its shares of OSR Holdings Co., Ltd. common stock at the closing of the business combination between Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd. Represents shares of common stock held by Bellevue Capital Management LLC. Kuk Hyoun Hwang is the managing partner of Bellevue Capital Management LLC and has voting and dispositive power over the shares held by BCM Europe AG. |
Common Stock
(I)
|
3,123,970 |
| 2024-06-23 | Kim Sang Hyun |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2024-05-27 | Lee Phil Geon |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2023-03-23 | Yoo David Jin |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor"), to Mr. Yoo for his service as Chief Financial Officer. |
Common Stock
|
20,000 |
| 2023-03-23 | Yoo David Jin |
Chief Financial Officer |
Award↑
Filing footnotes — Warrant for Common Stock (Direct)
Represents the warrants to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Yoo for his service as Chief Financial Officer. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments. |
Warrant for Common Stock
|
20,000 |
| 2023-03-23 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents the shares transferred by the Sponsor to Mr. David Jin Yoo for service as Chief Financial Officer. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
20,000 |
| 2023-03-23 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by the Sponsor to Mr. David Jin Yoo for service as Chief Financial Officer. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
20,000 |
| 2023-03-23 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Warrant for Common Stock (Direct)
Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. David Jin Yoo for his service as Chief Financial Officer. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments. |
Warrant for Common Stock
|
20,000 |
| 2023-03-23 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Warrant for Common Stock (Indirect)
Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. David Jin Yoo for his service as Chief Financial Officer. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments. |
Warrant for Common Stock
(I)
|
20,000 |
| 2023-02-21 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Direct)
Represents an additional 4,500 shares that were transferred from the Sponsor to the underwriters as a result of the underwriters exercising the over-allotment option in full. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
4,500 |
| 2023-02-21 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock (Direct)
Represents the shares that will no longer be forfeited by the Sponsor as a result of the underwriters exercising the over-allotment option in full. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
225,000 |
| 2023-02-21 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents an additional 4,500 shares that were transferred from the Sponsor to the underwriters as a result of the underwriters exercising the over-allotment option in full. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
4,500 |
| 2023-02-21 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↑
Filing footnotes — Common Stock (Indirect)
Represents the shares that will no longer be forfeited by the Sponsor as a result of the underwriters exercising the over-allotment option in full. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
225,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by the Sponsor to Mr. Steven Reed for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
20,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents the shares transferred by the Sponsor to Mr. Husun Euh for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
20,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Direct)
Represents the shares that were forfeited as a result of the underwriters' not exercising their over-allotment option. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
225,000 |
| 2023-02-14 | Chung In Chul |
Director |
Award↑
Filing footnotes — Warrant for Common Stock (Direct)
Represents the warrants to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Chung for his service as chair of the audit committee. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments. |
Warrant for Common Stock
|
20,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents the shares transferred by the Sponsor to Mr. In Chul Chung for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
20,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents the shares transferred by the Sponsor to Mr. Steven Reed for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
20,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Award↑
Filing footnotes — Common Stock (Direct)
The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
430,000 |
| 2023-02-14 | REED STEVEN |
Director |
Award↑
Filing footnotes — Warrant for Common Stock (Direct)
Represents the warrants to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Reed for his service as Chairman of the Board of Directors. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments. |
Warrant for Common Stock
|
20,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by the Sponsor to Mr. Rad Roberts for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
20,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Warrant for Common Stock (Indirect)
Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Dr. In Chul Chung for his service as Chairman of the Audit Committee. |
Warrant for Common Stock
(I)
|
20,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by the Sponsor to the underwriters. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
30,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents the shares transferred by the Sponsor to Mr. Jin Whan Park for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
20,000 |
| 2023-02-14 | Chung In Chul |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by Bellevue Global Life Sciences Investors LLC (the "Sponsor"), the sponsor of the Issuer, to Mr. Chung for his board service. |
Common Stock
|
20,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by the Sponsor to Mr. In Chul Chung for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
20,000 |
| 2023-02-14 | Roberts Rad |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer, to Mr. Roberts for his board service. |
Common Stock
|
20,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Buy↑
Filing footnotes — Private Placement Warrants (Direct)
The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock. The Private Placement Warrants are exercisable only to purchase whole shares of Common Stock at an exercise price of $11.50 per share, subject to adjustments. Each warrant will become exercisable 30 days after the Issuer's Public Offering. Each warrant will expire five years after the completion of the Issuer's Public Offering, or earlier upon redemption or liquidation. |
Private Placement Warrants
|
430,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Buy↑
Filing footnotes — Private Placement Warrants (Indirect)
The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock. The Private Placement Warrants are exercisable only to purchase whole shares of Common Stock at an exercise price of $11.50 per share, subject to adjustments. Each warrant will become exercisable 30 days after the Issuer's Public Offering. Each warrant will expire five years after the completion of the Issuer's Public Offering, or earlier upon redemption or liquidation. |
Private Placement Warrants
(I)
|
430,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by the Sponsor to Mr. Jin Whan Park for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
20,000 |
| 2023-02-14 | REED STEVEN |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by Bellevue Global Life Sciences Investors LLC (the "Sponsor"), the sponsor of the Issuer, to Mr. Reed for his board service. |
Common Stock
|
20,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents the shares transferred by the Sponsor to Mr. Rad Roberts for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
20,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Warrant for Common Stock (Direct)
Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Dr. In Chul Chung for his service as Chairman of the Audit Committee. |
Warrant for Common Stock
|
20,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Warrant for Common Stock (Indirect)
Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Steven Reed for his service as Chairman of the Board of Directors. |
Warrant for Common Stock
(I)
|
20,000 |
| 2023-02-14 | Euh Hosun |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer, to Mr. Euh for his board service. |
Common Stock
|
20,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by the Sponsor to Mr. Husun Euh for his board service. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor") whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
|
20,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Award↑
Filing footnotes — Common Stock (Indirect)
The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
430,000 |
| 2023-02-14 | Bellevue Global Life Science Investors LLC |
10% Owner |
Other↓
Filing footnotes — Warrant for Common Stock (Direct)
Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Steven Reed for his service as Chairman of the Board of Directors. |
Warrant for Common Stock
|
20,000 |
| 2023-02-14 | Park Jin Whan |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the shares transferred by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer, to Mr. Park for his board service. |
Common Stock
|
20,000 |
| 2023-02-14 | Hwang Kuk Hyoun |
Director, President and CEO, 10% Owner |
Other↓
Filing footnotes — Common Stock (Indirect)
Represents the shares that were forfeited as a result of the underwriters' not exercising their over-allotment option. Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
Common Stock
(I)
|
225,000 |